Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 1,000 shares of the stock in a transaction on Monday, March 24th. The shares were sold at an average price of $22.50, for a total value of $22,500.00. Following the sale, the chief financial officer now owns 23,000 shares in the company, valued at $517,500. The trade was a 4.17 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Benjamin Hohl also recently made the following trade(s):
- On Thursday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.41, for a total transaction of $66,332.50.
- On Wednesday, February 5th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.52, for a total value of $22,520.00.
- On Monday, January 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $21.59, for a total value of $70,167.50.
- On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.04, for a total value of $25,040.00.
- On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.51, for a total value of $20,259.00.
- On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.15, for a total value of $74,202.50.
Enliven Therapeutics Stock Down 2.0 %
NASDAQ:ELVN traded down $0.44 during mid-day trading on Friday, reaching $21.07. The company's stock had a trading volume of 192,187 shares, compared to its average volume of 274,965. Enliven Therapeutics, Inc. has a 1 year low of $15.96 and a 1 year high of $30.03. The stock has a fifty day moving average of $21.28 and a 200-day moving average of $23.74. The firm has a market capitalization of $1.03 billion, a PE ratio of -11.09 and a beta of 1.04.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. On average, analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several research analysts recently commented on ELVN shares. BTIG Research assumed coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They issued a "buy" rating and a $42.00 price target on the stock. HC Wainwright raised their target price on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $38.75.
Read Our Latest Stock Analysis on Enliven Therapeutics
Institutional Trading of Enliven Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Polar Capital Holdings Plc lifted its stake in shares of Enliven Therapeutics by 267.6% during the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock worth $53,768,000 after purchasing an additional 1,739,668 shares during the last quarter. Boxer Capital Management LLC purchased a new stake in shares of Enliven Therapeutics during the fourth quarter valued at about $15,106,000. FMR LLC boosted its holdings in shares of Enliven Therapeutics by 10.6% in the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company's stock valued at $160,804,000 after buying an additional 601,611 shares in the last quarter. Lord Abbett & CO. LLC purchased a new position in shares of Enliven Therapeutics in the 3rd quarter worth approximately $8,199,000. Finally, Janus Henderson Group PLC raised its stake in shares of Enliven Therapeutics by 43.0% during the 3rd quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company's stock worth $26,611,000 after acquiring an additional 313,019 shares in the last quarter. Institutional investors own 95.08% of the company's stock.
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
See Also
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
